Adial Pharmaceuticals Inc ADIL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADIL is a good fit for your portfolio.
News
-
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
-
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
-
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
-
Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
-
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
-
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
-
Adial Pharma to Conduct Two More AD04 Phase 3 Trials After Regulatory Feedback
Trading Information
- Previous Close Price
- $1.17
- Day Range
- $1.05–1.19
- 52-Week Range
- $0.77–8.88
- Bid/Ask
- $1.03 / $1.05
- Market Cap
- $4.44 Mil
- Volume/Avg
- 822,070 / 2.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.adialpharma.com
Valuation
Metric
|
ADIL
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.70 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
ADIL
|
---|---|
Quick Ratio | 8.93 |
Current Ratio | 9.48 |
Interest Coverage | — |
Quick Ratio
ADIL
Profitability
Metric
|
ADIL
|
---|---|
Return on Assets (Normalized) | −221.35% |
Return on Equity (Normalized) | −281.07% |
Return on Invested Capital (Normalized) | −279.77% |
Return on Assets
ADIL
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Shznqdxdt | Xcyvb | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Nrzkqxfmt | Nsxxln | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Hpglpysv | Kwyfkv | $118.7 Bil | |||
Moderna Inc
MRNA
| Gxkblwssf | Cdh | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Dxhkctys | Rxcxwby | $29.7 Bil | |||
argenx SE ADR
ARGX
| Nyvqwdgrg | Nqmq | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Ypvlykbqr | Npd | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Wpgqwfgk | Jgppzc | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Gjshqkfn | Hwhsf | $15.0 Bil | |||
Incyte Corp
INCY
| Thxmvvtd | Lnlxkb | $13.5 Bil |